These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 2753983

  • 1. The role of dopamine in nonmodulating hypertension.
    Gordon MS, Steunkel CA, Conlin PR, Hollenberg NK, Williams GH.
    J Clin Endocrinol Metab; 1989 Aug; 69(2):426-32. PubMed ID: 2753983
    [Abstract] [Full Text] [Related]

  • 2. Dopamine and nonmodulating hypertension.
    Williams GH, Gordon MS, Stuenkel CA, Conlin PR, Hollenberg NK.
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):112S-115S. PubMed ID: 2383375
    [Abstract] [Full Text] [Related]

  • 3. Dopaminergic modulation of aldosterone responsiveness to angiotensin II with changes in sodium intake.
    Gordon MB, Moore TJ, Dluhy RG, Williams GH.
    J Clin Endocrinol Metab; 1983 Feb; 56(2):340-5. PubMed ID: 6822640
    [Abstract] [Full Text] [Related]

  • 4. Abnormal norepinephrine and aldosterone responses to upright posture in nonmodulating hypertension.
    Conlin PR, Braley LM, Menachery AI, Hollenberg NK, Williams GH.
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1017-21. PubMed ID: 1400865
    [Abstract] [Full Text] [Related]

  • 5. Dopaminergic modulation of aldosterone secretion in the rat.
    Aguilera G, Catt KJ.
    Endocrinology; 1984 Jan; 114(1):176-81. PubMed ID: 6317344
    [Abstract] [Full Text] [Related]

  • 6. Acute dopaminergic inhibition of aldosterone secretion is independent of angiotensin II and adrenocorticotropin.
    Carey RM.
    J Clin Endocrinol Metab; 1982 Feb; 54(2):463-9. PubMed ID: 6274907
    [Abstract] [Full Text] [Related]

  • 7. Abnormal atrial natriuretic peptide and renal responses to saline infusion in nonmodulating essential hypertensive patients.
    Ferri C, Bellini C, Coassin S, Baldoncini R, Luparini RL, Perrone A, Santucci A.
    Circulation; 1994 Dec; 90(6):2859-69. PubMed ID: 7994831
    [Abstract] [Full Text] [Related]

  • 8. Dopaminergic receptor mechanisms modulating the renin-angiotensin system and aldosterone secretion: an overview.
    Missale C, Lombardi C, De Cotiis R, Memo M, Carruba MO, Spano PF.
    J Cardiovasc Pharmacol; 1989 Dec; 14 Suppl 8():S29-39. PubMed ID: 2483440
    [Abstract] [Full Text] [Related]

  • 9. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives.
    Redgrave J, Rabinowe S, Hollenberg NK, Williams GH.
    J Clin Invest; 1985 Apr; 75(4):1285-90. PubMed ID: 2985655
    [Abstract] [Full Text] [Related]

  • 10. Effect of sodium balance and calcium channel-blocking drugs on plasma aldosterone responses to infusion of angiotensin II in normal subjects and patients with essential hypertension.
    Anderson GH, Howland T, Domschek R, Streeten DH.
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1126-35. PubMed ID: 3760114
    [Abstract] [Full Text] [Related]

  • 11. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
    Carey RM, Thorner MO, Ortt EM.
    J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
    [Abstract] [Full Text] [Related]

  • 12. Lack of direct effect of dopamine on aldosterone secretion in vivo.
    Lun S, Espiner EA, Nicholls MG, Hart DS.
    Endocrinology; 1983 Jan; 112(1):60-3. PubMed ID: 6847834
    [Abstract] [Full Text] [Related]

  • 13. Effect of upright posture on the aldosterone responses to dopamine, metoclopramide, angiotensin II, and adrenocorticotropin.
    Malchoff CD, Hughes JM, Carey RM.
    J Clin Endocrinol Metab; 1987 Jul; 65(1):203-7. PubMed ID: 3034955
    [Abstract] [Full Text] [Related]

  • 14. Renal abnormalities in nonmodulating essential hypertension.
    Williams GH, Moore TJ, Hollenberg NK.
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):39-44. PubMed ID: 3037888
    [Abstract] [Full Text] [Related]

  • 15. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension.
    Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK.
    J Clin Invest; 1983 Dec; 72(6):2115-24. PubMed ID: 6358261
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of atrial natriuretic factor on angiotensin II- and adrenocorticotropin-stimulated aldosterone secretion.
    Aguilera G.
    Endocrinology; 1987 Jan; 120(1):299-304. PubMed ID: 3023030
    [Abstract] [Full Text] [Related]

  • 17. Aldosterone suppression with dopamine infusion in low-renin hypertension.
    Holland OB, Thomas C, Brown H, Schindewolf D, Hillier Y, Gomez-Sanchez C.
    J Clin Invest; 1983 Sep; 72(3):754-66. PubMed ID: 6309909
    [Abstract] [Full Text] [Related]

  • 18. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
    García-Robles R, Ruilope L, Mancheño E, Hurtado A, Alcázar JM, Varela C, de la Calle H, Rodicio JL, Sancho J.
    Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
    [Abstract] [Full Text] [Related]

  • 19. Influence of sodium homeostasis on dopaminergic modulation of aldosterone, renin, and prolactin secretion in man.
    Sowers JR, Glub MS, Eggena PH, Catania RA.
    J Clin Endocrinol Metab; 1982 Jan; 54(1):121-6. PubMed ID: 7033264
    [Abstract] [Full Text] [Related]

  • 20. Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.
    Carey RM, Vaughan ED, Peach MJ, Ayers CR.
    J Clin Invest; 1978 Jan; 61(1):20-31. PubMed ID: 338631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.